<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02538367</url>
  </required_header>
  <id_info>
    <org_study_id>YH12852-102</org_study_id>
    <nct_id>NCT02538367</nct_id>
  </id_info>
  <brief_title>Phase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation</brief_title>
  <official_title>A Randomized, Double-blind/Open-label, Placebo/Active-controlled, Single/Multiple Dose, Parallel, Phase 1/2a Trial to Evaluate the Safety, Tolerability, PK , PD of YH12852 in Healthy Subjects and Patients With Functional Constipation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yuhan Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yuhan Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, double-blind/open-label, placebo/active-controlled, single/multiple dose,
      parallel, phase 1/2a trial to evaluate the safety, tolerability, pharmacokinetics and
      pharmacodynamics of YH12852 in healthy subjects and patients with functional constipation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cmax (IR/DR multiple dose cohort and Multiple low-dose IR cohort)</measure>
    <time_frame>Day 1 pre-dose (0 hr) ~ 24 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUC0-24 (IR/DR multiple dose cohort and Multiple low-dose IR cohort)</measure>
    <time_frame>Day 1 pre-dose (0 hr) ~ 24 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tmax(IR/DR multiple dose cohort and Multiple low-dose IR cohort)</measure>
    <time_frame>Day 1 pre-dose (0 hr) ~ 24 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C(IR multiple dose cohort)</measure>
    <time_frame>Day 5, 10, 12 and 13</time_frame>
    <description>CD5, CD10, CD12, CD13</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss(IR/DR multiple dose cohort and Multiple low-dose IR cohort)</measure>
    <time_frame>Day 14</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax,ss (DR single dose cohort)</measure>
    <time_frame>Day 1: pre-dose (0 hr) ~ 62hr and 86 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>AUClast (DR single dose cohort)</measure>
    <time_frame>Day 1: pre-dose (0 hr) ~ 62hr and 86 hrs post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>C(DR multiple dose cohort and Multiple low-dose IR cohort)</measure>
    <time_frame>Day 5, 13 and 14</time_frame>
    <description>CD5, CD13, CD14</description>
  </primary_outcome>
  <number_of_arms>14</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Functional Constipation</condition>
  <arm_group>
    <arm_group_label>YH12852 IR 0.05mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 IR 0.1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 IR 0.3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 IR 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 IR 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 IR 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 IR 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 DR1 0.5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 DR1 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 DR1 2mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 DR1 4mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>YH12852 DR2 8mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Prucalopride 2mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 0.05mg</intervention_name>
    <arm_group_label>YH12852 IR 0.05mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 0.1mg</intervention_name>
    <arm_group_label>YH12852 IR 0.1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 0.3mg</intervention_name>
    <arm_group_label>YH12852 IR 0.3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 0.5mg</intervention_name>
    <arm_group_label>YH12852 IR 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 1mg</intervention_name>
    <arm_group_label>YH12852 IR 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 2mg</intervention_name>
    <arm_group_label>YH12852 IR 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 IR 3mg</intervention_name>
    <arm_group_label>YH12852 IR 3mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 DR1 0.5mg</intervention_name>
    <arm_group_label>YH12852 DR1 0.5mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 DR1 1mg</intervention_name>
    <arm_group_label>YH12852 DR1 1mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 DR1 2mg</intervention_name>
    <arm_group_label>YH12852 DR1 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 DR1 4mg</intervention_name>
    <arm_group_label>YH12852 DR1 4mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>YH12852 DR2 8mg</intervention_name>
    <arm_group_label>YH12852 DR2 8mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prucalopride 2mg</intervention_name>
    <arm_group_label>Prucalopride 2mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects must be willing and able to provide written informed consent.

          2. BMI within the range 18 to 25 kg/m2.

        Exclusion Criteria:

          1. History of positive serologic evidence for infectious disease including HBsAg,
             anti-HCV, anti-HIV.

          2. Clinically significant lab/ECG abnormalities in the opinion of the investigator.

          3. WOCBP who are unwilling or unable to use an adequate contraceptive method to avoid
             pregnancy for the entire study. WOCBP include any female who has experienced menarche
             and who has not undergone successful surgical sterilization (hysterectomy, bilateral
             tubal ligation, bilateral tubectomy, or bilateral oophorectomy) or is not
             postmenopausal. Post menopause is defined as amenorrhea for ≥ 12 consecutive months
             without another cause.

             Clinically acceptable contraceptive methods for this study: intrauterine devices
             (e.g., loop), physical barrier method (e.g., diaphragm, uterine cap, condom) with
             chemical barrier method (e.g., spermicide), sterile partner, practicing abstinence.

          4. WOCBP who are willing to use hormonal methods or hormone-releasing device(e.g.,
             mirena, implanon) for the entire study.

          5. WOCBP who are pregnant or breastfeeding.

          6. WOCBP with a positive pregnancy test prior to randomization.

          7. Males who have not received a vasectomy must agree to use contraceptive methods
             defined in (a) and refrain from donating sperm throughout the study.

          8. Presence of uncontrolled or severe medical illness.

          9. Presence of a disease that require surgery at any time during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital and College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 21, 2015</study_first_submitted>
  <study_first_submitted_qc>August 30, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2015</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constipation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

